Q4 2011 Earnings Call
February 08, 2012 8:30 am ET
Doug Guarino - Director of Corporate Communications & Corporate Relations
Ron Zwanziger - Chairman of the Board, Chief Executive Officer and President
David A. Teitel - Chief Financial Officer, Principal Accounting Officer, Vice President and Treasurer
Ashim Anand - Natixis Bleichroeder LLC, Research Division
John M. Putnam - Capstone Investments, Research Division
Peter Lawson - Mizuho Securities USA Inc., Research Division
Zarak Khurshid - Wedbush Securities Inc., Research Division
Gregory J. Simpson - Wunderlich Securities Inc., Research Division
Isaac Ro - Goldman Sachs Group Inc., Research Division
Jonathan P. Groberg - Macquarie Research
Bill Bonello - RBC Capital Markets, LLC, Research Division
Jeffrey Frelick - Canaccord Genuity, Research Division
Nicholas Jansen - Raymond James & Associates, Inc., Research Division
Good morning, and welcome to the Alere Inc. conference call to discuss fourth quarter 2011 results. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Doug Guarino. Please go ahead.
Thank you, Amy. Good morning, and welcome to the Alere conference call to discuss our results for the quarter and year ended December 31, 2011. We are joined today by Ron Zwanziger, Chairman and CEO; and Dave Teitel, CFO.
Before we get to that discussion though, I would first like to draw your attention to the fact that certain matters discussed in this conference call will constitute forward-looking statements within the meaning of the U.S. securities laws. These statements reflect our current views with respect to future events and financial performance and are based on management's current assumptions and information currently available. Actual results and the timing of certain events could differ materially from those projected or contemplated by the forward-looking statements due to numerous factors including, without limitation, our ability to successfully acquire and integrate our acquisitions and to recognize the expected benefits of restructuring and new business activities; our exposure to changes in interest rates and foreign currency exchange rates; our ability to successfully develop and commercialize products; the market acceptance of our products; continued acceptance of health management services by payers, providers and patients; our ability to develop enhanced health management programs through the integrated use of innovative diagnostic and monitoring devices, and to recognize the expected benefits of this strategy; the impact of health care reform legislation as well as future reform initiatives; the content and timing of decisions by regulatory authorities as well as the impact of changes in reimbursement policy and budgetary constraints, both in the United States and abroad; the effective pending and future legal proceedings in our financial performance; and the risks and uncertainties described in our periodic reports filed with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2010, as well as in our quarterly reports on Form 10-Q. Our company undertakes no obligation to update forward-looking statements.